546 related articles for article (PubMed ID: 20086184)
1. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
Gales BJ; Bailey EK; Reed AN; Gales MA
Ann Pharmacother; 2010 Feb; 44(2):360-6. PubMed ID: 20086184
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults.
Dorosch T; Ganzer CA; Lin M; Seifan A
Curr Pain Headache Rep; 2019 Sep; 23(11):85. PubMed ID: 31515634
[TBL] [Abstract][Full Text] [Related]
5. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation.
Jennings DL; Taber DJ
Ann Pharmacother; 2008 Jan; 42(1):116-20. PubMed ID: 18094340
[TBL] [Abstract][Full Text] [Related]
6. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
Epstein BJ; Gums JG
Ann Pharmacother; 2005 Mar; 39(3):470-80. PubMed ID: 15701766
[TBL] [Abstract][Full Text] [Related]
8. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
[TBL] [Abstract][Full Text] [Related]
9. Migraine prophylaxis with drugs influencing the renin-angiotensin system.
Stovner LJ
Eur J Neurol; 2007 Jul; 14(7):713-4. PubMed ID: 17594324
[No Abstract] [Full Text] [Related]
10. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
12. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
Tokmakova M; Solomon SD
Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
[TBL] [Abstract][Full Text] [Related]
14. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the renin-angiotensin-aldosterone system and cough.
Lacourcière Y; Lefebvre J
Can J Cardiol; 1995 Aug; 11 Suppl F():33F-39F. PubMed ID: 7664216
[TBL] [Abstract][Full Text] [Related]
16. Discordant responses to two classes of drugs acting on the renin-angiotensin system.
Sever PS; Chang CL
J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1):25-30. PubMed ID: 11881062
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin inhibition in heart failure.
McMurray JJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S17-22. PubMed ID: 15526237
[TBL] [Abstract][Full Text] [Related]
18. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
19. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
Jorde UP
Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
